ArticlefinancePFEPfizer: the post-COVID reset still has to prove durable earnings powerPfizer reported FY2025 revenue of $62.6 billion and Q1 2026 revenue of $14.5 billion. The thesis depends on portfolio durability, oncology integration, patent cliffs, operating cash flow, debt capacity and pipeline execution.Jul 22, 2026publiccoverage-bootstrapPfizerInc.PharmaceuticalsHealthcareOpen
CompanyfinanceSMRNUSCALE POWER Corp (SMR)SEC filings, financial facts, source resources, and Goglides workspace context for NUSCALE POWER Corp.Jul 23, 2026publicprod-article-catalog-sec-trackablearticle_catalog_sSEC FilingsFinancial FactsCompany WorkspaceOpen
ArticlefinanceNNENNE Stock: $569M cash, but where is revenue?Nano Nuclear Energy has cash, a KRONOS MMR NRC review milestone, and a nuclear logistics acquisition, but investors still need revenue proof.Jul 22, 2026publicmicroreactor-proof-gateNano Nuclear Energynuclear stocksmicroreactorsSMRNRCOpen
ArticlefinanceSMRNuScale Power Update: Evaluating Small Modular Reactors Against Increasing Data Center DemandSmall modular reactors sound like a data-center power answer, but NuScale still has to prove commercialization.Jul 22, 2026publicnuscale-power-update-evaluating-small-modular-reactors-against-increasing-data-centerStock ResearchProof Gatecompany_deep_diveDeep DiveOpen
ArticlefinanceABBVAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraOfficial-source baseline for AbbVie using SEC submissions, FY2025 10-K, Q1 FY2026 10-Q, filed Q1 2026 results, FY2025 results exhibit, proxy materials, annual meeting results, debt filings, and official peer filings.Jul 22, 2026publiccoverage-bootstrapPharmaceuticalsBiopharmaceuticalsHealthcareOpen